Video

Pharmaceutical CEO Leadership: Collaboration in Pharma – Choosing Partners

In this segment, members of the Pharmaceutical CEO Leadership: Collaboration in Pharma panel share what to look for in a collaborative partner and the benefit of entering into win-win situations. They also promote the potential of looking toward more unconventional types of partners and reveal what it takes to maintain successful relationships.

Read the full article "Capitalizing on Collaboration."

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Gen Li
Gen Li
Gen Li
Dr. Ben Zeskind
Gen Li
Dr. Ben Zeskind
Gen Li
Dr. Ben Zeskind
Related Content
Early Trial Success Signals Promise for GT-02287 in Parkinson’s Disease Treatment
August 2nd 2025

Early Trial Success Signals Promise for GT-02287 in Parkinson’s Disease Treatment

Don Tracy, Associate Editor
Gene Mack, CEO, GAIN Therapeutics, shares how growing clinician confidence and strong early experiences helped accelerate enrollment in the company’s Phase Ib Parkinson’s disease trial.
Exploring the Promise of E7386 and Lenvatinib Combination Therapy in Endometrial Carcinoma
August 2nd 2025

Exploring the Promise of E7386 and Lenvatinib Combination Therapy in Endometrial Carcinoma

Don Tracy, Associate Editor
Corina Dutcus, SVP, oncology global clinical development lead at Eisai, discusses the potential of the E7386 and lenvatinib combination to address unmet needs in second-line treatment for endometrial carcinoma patients.
Collaborating for Smarter AI Solutions in Oncology at Johnson and Johnson
August 2nd 2025

Collaborating for Smarter AI Solutions in Oncology at Johnson and Johnson

Don Tracy, Associate Editor
Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine, discusses the importance of collaboration across the healthcare community to develop inclusive and effective AI solutions that enhance decision-making and patient outcomes in oncology.
AbbVie Positions Temab-A ADC for Tumor-Agnostic Use in Multiple Cancers
August 2nd 2025

AbbVie Positions Temab-A ADC for Tumor-Agnostic Use in Multiple Cancers

Don Tracy, Associate Editor
Pedro Valencia, VP, asset strategy leadership, oncology, AbbVie, explains how the company is advancing Temab-A across multiple tumor types targeting c-Met, with the goal of establishing it as a pipeline-in-a-molecule.
What Drives AbbVie’s Solid Tumor Strategy Following ASCO 2025 Insights
August 2nd 2025

What Drives AbbVie’s Solid Tumor Strategy Following ASCO 2025 Insights

Don Tracy, Associate Editor
Pedro Valencia, VP, asset strategy leadership, oncology, outlines how unmet need, treatment stagnation, and pipeline innovation shape the company’s approach to solid tumor oncology following key data presented at ASCO 2025.
Undertreated but High-Risk: The Hidden Health Crisis Facing 50+ Americans
August 2nd 2025

Undertreated but High-Risk: The Hidden Health Crisis Facing 50+ Americans

Don Tracy, Associate Editor
Leandro Boer, MD, PhD, VP, US general medicines, Amgen, explains why many high-risk Americans aged 50+ remain undertreated for cardiovascular disease, citing insurance gaps, risk misperceptions, and complex guidelines.